Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Operating Leases for 8 consecutive years, with $210.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 6.22% year-over-year to $210.5 million; the trailing twelve-month figure through Jun 2026 stood at $210.5 million (down 6.22% YoY), and the FY2025 full-year result was $225.1 million, down 1.94% from the prior year.
• Operating Leases declined to $210.5 million in Q2 2026 per ALNY's latest filing, from $218.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $277.4 million in Q1 2022 and bottomed at $210.5 million in Q2 2026.
• Historically, Operating Leases has averaged $241.9 million across 5 years, with a median of $238.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Operating Leases dropped 8.32% in 2024, then slipped 1.94% in 2025.
• Over 5 years, Operating Leases stood at $261.3 million in 2022, then decreased by 6.98% to $243.1 million in 2023, then slipped by 5.58% to $229.5 million in 2024, then decreased by 1.94% to $225.1 million in 2025, then slipped by 6.48% to $210.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $210.5 million, $218.0 million, and $225.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.